US Patent

US8242104 — Benzoxazepin P13K inhibitor compounds and methods of use

Composition of Matter · Assigned to F Hoffmann La Roche AG · Expires 2030-09-27 · 4y remaining

Vulnerability score 23/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects benzoxazepin compounds that inhibit lipid kinases, including p110 alpha and other PI3K isoforms, for treating disorders such as cancer.

USPTO Abstract

Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US8242104
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-09-27
Drug substance claim
Yes
Drug product claim
Yes
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.